Markus Blaurock1, Chia-Jung Busch2. 1. Klinik für HNO-Heilkunde, Kopf- und Halschirurgie, Universitätsmedizin Greifswald, Ferdinand Sauerbruch Str. 1, 17475, Greifswald, Deutschland. Markus.Blaurock@med.uni-greifswald.de. 2. Klinik für HNO-Heilkunde, Kopf- und Halschirurgie, Universitätsmedizin Greifswald, Ferdinand Sauerbruch Str. 1, 17475, Greifswald, Deutschland.
Abstract
BACKGROUND: This article summarizes new findings on chemo- and targeted therapy of head and neck squamous cell carcinoma presented at the 2021 American Society of Clinical Oncology (ASCO) conference. OBJECTIVE: Relevant publications were evaluated and summarized. METHODS: The abstract database of the 2021 ASCO conference was searched. Publications were selected if they focused on chemo- or targeted therapies in head and neck squamous cell carcinoma. Publications covered in other articles of this issue were omitted, as were study proposals without results. RESULTS: The authors present six articles. Dosage and novel forms of application are shown for cisplatin. Cetuximab is used in the neoadjuvant setting and for progressive disease following immune therapy. Lastly, two new drugs in the form of liposomal irinotecan and the mHRAS inhibitor tipifarnib are discussed. CONCLUSION: Patient-specific and possibly local application of cisplatin might be considered in the future. Moreover, mHRAS inhibition might also be useful for selected patients after sequencing.
BACKGROUND: This article summarizes new findings on chemo- and targeted therapy of head and neck squamous cell carcinoma presented at the 2021 American Society of Clinical Oncology (ASCO) conference. OBJECTIVE: Relevant publications were evaluated and summarized. METHODS: The abstract database of the 2021 ASCO conference was searched. Publications were selected if they focused on chemo- or targeted therapies in head and neck squamous cell carcinoma. Publications covered in other articles of this issue were omitted, as were study proposals without results. RESULTS: The authors present six articles. Dosage and novel forms of application are shown for cisplatin. Cetuximab is used in the neoadjuvant setting and for progressive disease following immune therapy. Lastly, two new drugs in the form of liposomal irinotecan and the mHRAS inhibitor tipifarnib are discussed. CONCLUSION: Patient-specific and possibly local application of cisplatin might be considered in the future. Moreover, mHRAS inhibition might also be useful for selected patients after sequencing.
Authors: Anne W Wendrich; Justin E Swartz; Sandra I Bril; Inge Wegner; Alexander de Graeff; Ernst J Smid; Remco de Bree; Ajit J Pothen Journal: Oral Oncol Date: 2017-06-05 Impact factor: 5.337
Authors: Neha Amin; Christopher A Maroun; Margueritta El Asmar; Hosam H Alkhatib; Meytal Guller; Matthew E Herberg; Gangcai Zhu; Tanguy Y Seiwert; Drew Pardoll; David W Eisele; Carole Fakhry; Christine G Gourin; Rajarsi Mandal Journal: Head Neck Date: 2021-11-26 Impact factor: 3.147
Authors: Alan L Ho; Irene Brana; Robert Haddad; Jessica Bauman; Keith Bible; Sjoukje Oosting; Deborah J Wong; Myung-Ju Ahn; Valentina Boni; Caroline Even; Jerome Fayette; Maria José Flor; Kevin Harrington; Sung-Bae Kim; Lisa Licitra; Ioanna Nixon; Nabil F Saba; Stephan Hackenberg; Pol Specenier; Francis Worden; Binaifer Balsara; Mollie Leoni; Bridget Martell; Catherine Scholz; Antonio Gualberto Journal: J Clin Oncol Date: 2021-03-22 Impact factor: 50.717